MAZE · Maze Therapeutics, Inc.

Maze Therapeutics’ Q1 2026 results reflect a strategic inflection point: the company transitioned from pure R&D investment to early-stage value generation, evidenced by $20.0 million in license revenue tied to a Shionogi milestone for MZE001 — its first such recognition and a validation of its platform’s external partnering potential. Net loss improved year-over-year ($24.2M vs. $32.8M), not from cost discipline but from this non-recurring revenue offsetting higher operating expenses. R&D spend rose 24% year-over-year to $34.1M, directly attributable to active clinical execution — specifically the completed Phase 2 HORIZON trial of MZE829 in AMKD and preparatory work for two upcoming Phase 2 trials of MZE782 (in PKU and CKD). G&A increased 59% to $12.4M, reflecting scaling infrastructure and equity compensation, consistent with a maturing clinical-stage biotech. Critically, the press release anchors investor focus on clinical de-risking: the HORIZON topline data delivered the first-ever proof-of-concept for an APOL1 inhibitor in genetically defined AMKD, with differentiated efficacy across subpopulations (e.g., 61.8% uACR reduction in FSGS patients) and a clean safety profile — enabling a clear path to a pivotal trial. Combined with $528M total available liquidity post-April financing and milestone, the company has extended its cash runway into 2029, providing substantial optionality to advance multiple programs without near-term dilution risk. Management’s commentary emphasizes disciplined clinical execution over financial metrics, signaling that near-term catalysts — including additional HORIZON data in late 2026/early 2027 and initiation of MZE782 trials — will drive valuation more than quarterly P&L fluctuations.